Guangzhou Bio-gene Technology Co., Ltd is a Chinese biotechnology company based in Guangzhou city, Guangdong Province, specializing in the discovery, development and delivery of novel cell therapies for the treatment of blood malignancies and solid tumors. Since founded in 2015, Guangzhou Bio-gene has been a fully owned subsidiary of HEDY Group Co., LTD . 

 

In the past five years, Guangzhou Bio-gene has established its own product pipeline, including a variety of chimeric antigen receptor T cells products, such as anti-CD19 CAR-T, CD19-CD22 bispecific CAR-T, novel target CAR-T and universal CAR-T, etc. By collaborating with several top Chinese hospitals, we demonstrated that our next generation of CAR-T product could be safely used in patients while efficiently eliminate the tumor cells. Guangzhou Bio-gene sets the safety of patients to our highest priority, assuring our procedures to follow up-to-date GMP regulations and guidelines. 

If you are interested to know more about our company, please contact us by phone or email:  info@gzbiogene.com； Tel(Fax): +86 20 32030437

CAR-T Technology